Development and internal validation of a radiomics-clinical combined model for predicting axillary pathological complete response in clinically node-positive breast cancer patients after neoadjuvant chemotherapy - Scorecard - MDSpire
Advertisement
Development and internal validation of a radiomics-clinical combined model for predicting axillary pathological complete response in clinically node-positive breast cancer patients after neoadjuvant chemotherapy
Clinical Scorecard: Creation and internal assessment of a combined radiomics-clinical model for forecasting axillary pathological complete response in breast cancer patients with clinically positive nodes following neoadjuvant chemotherapy
At a Glance
Category
Detail
Condition
Breast cancer with clinically positive nodes
Key Mechanisms
Neoadjuvant chemotherapy and radiomics for predicting axillary pathological complete response
Target Population
Clinically node-positive breast cancer patients
Care Setting
Oncology clinical practice
Key Highlights
Overall apCR rate was 43.5% in the study cohort.
The combined model achieved a validation AUC of 0.703.
The combined model outperformed the radiomics-only model significantly.
Guideline-Based Recommendations
Diagnosis
Assessment of axillary response following neoadjuvant chemotherapy.
Management
Consideration of surgical de-escalation from axillary lymph node dissection to sentinel lymph node biopsy based on apCR prediction.
Monitoring & Follow-up
Regular evaluation of clinical and radiomic predictors for apCR.
Risks
Potential morbidity associated with axillary lymph node dissection, including lymphedema and chronic pain.
Patient & Prescribing Data
386 clinically node-positive breast cancer patients
Neoadjuvant chemotherapy is standard for locally advanced cases.
